Item 4.02 restatements carry significant legal and reputational risk, often triggering shareholder lawsuits and Nasdaq compliance questions. The proximity of the original 10-Q filing (May 12) to this restatement (May 22) suggests a rushed filing or inadequate controls. Monitor for NASDAQ listing qualification questions, potential securities litigation, and any auditor resignation. The reaffirmed FY2026 guidance is non-binding and should be heavily discounted given the control issues just identified.
Price Chart
Executive Summary
NeuroOne Medical Technologies filed an 8-K announcing a restatement of its Q2 FY2026 financials (quarter ended March 31, 2026) due to a revenue recognition error from a customer order modification at quarter-end. Revenue was overstated by ~$529K, gross profit by ~$296K, and net loss was understated by ~$296K. The company reaffirmed FY2026 product revenue guidance of at least $10.5M, stated no prior periods or cash position were impacted, and attributed the error to inadequate internal controls. Restatement follows just 10 days after the original 10-Q was filed on May 12, 2026, and is a clearly negative event despite management's spin.
Key Facts
- Revenue overstated by ~$529K for the three and six months ended March 31, 2026 (originally reported revenue of $2.4M for the quarter)
- Gross profit overstated by ~$296K; operating loss and net loss understated by ~$296K for the same periods
- Inventory understated by ~$233K and total assets overstated by ~$296K as of March 31, 2026
- Audit Committee determined on May 21, 2026 that prior financial statements should no longer be relied upon
- Error attributed to inadequate design and implementation of internal controls to evaluate customer modified purchase orders
- Company reaffirms FY2026 product revenue guidance of at least $10.5M and states no impact on cash position or prior periods
- Original 10-Q was filed only 10 days prior on May 12, 2026; restatement announcement on May 22, 2026
- No intentional misconduct found; auditor Baker Tilly US, LLP notified
Financial Impact
Revenue restated downward by ~$529K (22% of originally reported $2.4M quarterly revenue), gross profit reduced by ~$296K, net loss increased by ~$296K. Total assets reduced by ~$296K, inventory increased by ~$233K.
Risk Factors
- Securities class-action lawsuit risk is high given the restatement and rapid reversal of filed financials
- Nasdaq may question continued listing compliance or require additional disclosures
- Subsequent restatement could reveal further errors or require additional prior-period adjustments
- Investor confidence and credibility severely damaged; capital-raising ability impaired for a $34M market cap company
- Potential for auditor resignation or enhanced scrutiny if internal control deficiencies are material
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-060600 |
| Document: ea029192501ex99-1.htm | 0001213900-26-060600 |
| Document: 0001213900-26-060600-index-headers.html | 0001213900-26-060600 |
| Document: 0001213900-26-060600-index.html | 0001213900-26-060600 |
| Document: 0001213900-26-060600.txt | 0001213900-26-060600 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 22d ago | 8-K | $1.12 $1.13 | ▲ +1.35% | ▲ +0.80% | $0.8499 (−23.78%) |
Oct 5, 2026 22d ago | Press Release | $1.12 $1.13 | ▲ +1.35% | ▲ +0.80% | $0.8499 (−23.78%) |
Aug 27, 2026 8w ago | 8-K | $1.98 $1.77 | ▼ −10.61% | ▼ −10.38% | $0.8499 (−57.08%) |
Aug 13, 2026 10w ago | 8-K | $1.83 $1.94 | ▲ +6.01% | ▲ +6.21% | $0.8499 (−53.56%) |
Jun 12, 2026 19w ago | 424B5 / 8-K | $3.32 $3.25 | ▲ +2.11% | ▲ +1.51% | $0.8499 (+74.40%) |
May 22, 2026 22w ago | 8-K | $3.87 $3.73 | ▲ +3.62% | ▲ +3.63% | $0.8499 (+78.04%) |
May 12, 2026 24w ago | 8-K | $4.39 $4.51 | ▲ +2.73% | ▲ +2.16% | $0.8499 (−80.64%) |
May 4, 2026 25w ago | 8-K | $4.49 $4.43 | ▼ −1.34% | ▼ −2.13% | $0.8499 (−81.07%) |
Apr 30, 2026 25w ago | 8-K | $4.70 $4.35 | ▼ −7.45% | ▼ −7.67% | $0.8499 (−81.92%) |
Feb 25, 2026 34w ago | 8-K | $4.15 $4.02 | ▼ −3.04% | ▼ −2.59% | $0.8499 (−79.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers